CRI-ENCI Ninth International Cancer
Immunotherapy Conference

TRANSLATING
SCIENCE INTO
SURVIVAL

Sept. 10-12, 2025 | Utrecht, The Netherlands

Pre-Conference Program: Sept. 9, 2025

CICON25 Abstract Submission

Abstract submission for CICON is now open through June 1, 2025.

To submit an abstract, presenters must first register for CICON25. Once registered, you will receive a unique conference registration number. This number is required for the online abstract submission. Abstract submissions cannot be completed without prior conference registration and the associated registration number.

Abstracts will undergo a blind peer-review process.

Abstracts will be rejected if they fall outside the scope of the meeting (e.g., not related to cancer immunology or immunotherapy), if they are purely commercial in nature, or if they clearly violate scientific standards.

Authors of top-rated abstracts will be offered the opportunity to present short talks. 

Contact for questions regarding abstracts
Astrid Schnabel (Mornings)
Phone: +49 611 204809 277
Email: cicon@wikonect.de

ABSTRACT SUBMISSION CATEGORIES

New Targets and Lead Structures
Submit your abstract in this session if you report on an exciting new target structure, or if you work on the development of innovative lead structures or therapeutic platforms.

Tumor Microenvironment and Immunosuppression
This session is dedicated to the complexity of cancer-immune interactions in the tumor microenvironment and to understanding the suppressive mechanisms that constrain anti-tumor immune responses.

Computational Immunology
Computational immunology is all about developing and utilizing computational tools that help us to analyze large amounts of data and harnessing AI models to improve cancer immunotherapy.

Cellular Therapies
From T-cell receptor treatments to chimeric antigen receptor innovations and beyond: This category covers all approaches in cellular therapy, encompassing diverse cell types and therapeutic strategies.

Biomarker Strategies
Accurate biomarkers are essential for the successful translation of cancer immunotherapies. If you have novel insights into predicting treatment-related effects such as response and toxicity, we encourage you to submit your abstract under this category.

 

Presenting your work

All accepted abstracts are presented as posters. Through a blind evaluation by our abstract review committee members, highly rated abstracts are proffered for consideration as short talk presentations.


Please download the Presentation Guidelines above for additional information.